Dialysis facilities in the US are financially rewarded for higher rates of home dialysis and kidney transplant, but facilities that serve patients with high social risk might have a harder time meeting these goals. JAMA Associate Editor Karen E. Joynt Maddox, MD, MPH, speaks with Amal N. Trivedi, MD, MPH, of Brown University, about how this plays out under the ESRD Treatment Choices Model. Related Content: Social Risk and Dialysis Facility Performance in the First Year of the ESRD Treatment Choices Model

Alpha-gal syndrome is a food allergy to red meat products that develops after affected individuals are bitten by a tick. JAMA Deputy Editor Kristin Walter, MD, MS, discusses alpha-gal syndrome with author Mariel R. Benjamin, MD, assistant professor in the Division of Allergy and Clinical Immunology at Michigan Medicine. Related Content: What Is Alpha-Gal Syndrome?

The effects of private equity acquisition of US hospitals on the quality of inpatient care and patient outcomes remain largely unknown. JAMA Associate Editor Karen E. Joynt Maddox, MD, MPH, spoke with author Zirui Song, MD, PHD, of Massachusetts General Hospital, about a recent study showing that private equity acquisition was associated with increased hospital-acquired adverse events. Related Content: Changes in Hospital Adverse Events and Patient Outcomes Associated With Private Equity Acquisition

Does reducing dietary sodium benefit patients already taking antihypertensive medication? JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, speaks with author Norrina Allen, PhD, MPH, from Northwestern University, about the effect of dietary sodium on blood pressure. Related Content: Effect of Dietary Sodium on Blood Pressure

Cannabis use is increasing among reproductive-age individuals. JAMA Deputy Editor Linda Brubaker, MD, MS, discusses the associated risks of cannabis exposure during pregnancy with Torri D. Metz, MD, MS, University of Utah Health. Related Content: Cannabis Exposure and Adverse Pregnancy Outcomes Related to Placental Function

Bilateral renal agenesis results in lethal neonatal pulmonary hypoplasia. New evidence from an amnioinfusion trial is available. JAMA Deputy Editor Linda Brubaker, MD, MS, discusses the results from the Renal Anhydramnios Fetal Therapy Trial with Meredith A. Atkinson, MD, MHS, Johns Hopkins University, and Johnathan M. Davis, MD, Tufts University. Related Content: Neonatal Survival After Serial Amnioinfusions for Bilateral Renal Agenesis

Cervical cancer screening is effective when done as recommended. JAMA Deputy Editor Linda Brubaker, MD, speaks with Rachel L. Winer, PhD, MPH, of the University of Washington, about a recent trial in JAMA that compared cervical cancer screening strategies, including direct-mail and opt-in approaches for human papillomavirus (HPV) self-sampling. Related Content: Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits

Small-volume blood collection tubes may decrease red blood cell transfusions in intensive care units without affecting laboratory analysis. JAMA Associate Editor Christopher W. Seymour, MD, MSc, discusses the results and implications of the STRATUS trial with Deborah M. Siegal, MD, MSc, of Ottawa Hospital Research Institute. Related Content: Small-Volume Blood Collection Tubes to Reduce Transfusions in Intensive Care

Fitness trackers are a group of devices including watches, phones, and rings that track physical activity. JAMA Executive Editor Gregory Curfman, MD, speaks with I-Min Lee, MBBS, ScD, professor of medicine at Harvard Medical School and professor of epidemiology at Harvard T.H. Chan School of Public Health, about using fitness trackers to guide advice on activity prescription. Related Content: Fitness Trackers to Guide Advice on Activity Prescription

JAMA Senior Editor Kristin Walter, MD, MS, and Lawrence O. Gostin, JD, JAMA Legal and Global Health Correspondent and Faculty Director of the O’Neill Institute for National and Global Health Law at Georgetown University, discuss the Inflation Reduction Act, which for the first time allows the Centers for Medicare & Medicaid Services to negotiate prescription drug prices with drug manufacturers. Related Content: Medicare’s Historic Prescription Drug Price Negotiations